China's WuXi explores sale of pharma units as US restrictions loom, FT reports

Reuters10-03

Oct 3 (Reuters) - Chinese biotech companies WuXi AppTec

and WuXi Biologics , which are being targeted by a forthcoming U.S. national security legislation, are working on sales of some of their operations, the Financial Times reported on Thursday, citing people familiar with the matter.

WuXi AppTec has put its cell and gene therapy manufacturing arm WuXi Advanced Therapies, which operates four laboratories and manufacturing facilities in Philadelphia, up for sale, the newspaper reported.

WuXi Biologics is also working with advisers to test interest in some of its European production facilities, FT reported, citing three people familiar with the situation.

(Reporting by Rishabh Jaiswal in Bengaluru; Editing by Sonia Cheema)

((rishabh.jaiswal@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment